Business Description
Sagimet Biosciences is a US-based drug development company focused on treating serious conditions linked to metabolic and tissue-scarring disorders, including liver disease, acne, and certain cancers. Its lead medicine, Denifanstat, is a once-daily oral treatment that works by blocking a specific enzyme involved in fat production in the body. The company is also advancing additional drug candidates targeting acne and hard-to-treat cancers such as glioblastoma. Founded in 2006 and based in San Mateo, California, the company operates under a name it adopted in 2019.
